EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access

Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis

Tanawin Nopsopon, Grace Lassiter, Ming-Li Chen, G Caleb Alexander, Corinne Keet, Hwanhee Hong, Ayobami Akenroye

Journal of Allergy and Clinical Immunology · 2023-03 · 151 (3) · 747-755

DOI: 10.1016/j.jaci.2022.11.021 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-03. Verfasst von Tanawin Nopsopon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Harvard T.H. Chan School of Publi…. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Pulmonary Eosinophilia, Biological Products. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, National Institute on Minority Health and Health Disparities, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: It is unclear how the efficacy of tezepelumab, approved for the treatment of type 2 high and low asthma, compares to the efficacy of other biologics for type 2-high asthma. OBJECTIVES: We sought to conduct an indirect comparison of tezepelumab to dupilumab, benralizumab, and mepolizumab in the treatment of eosinophilic asthma. METHODS: The investigators conducted a systematic review and Bayesian network meta-analyses. They identified randomized controlled trials indexed in PubMed, Embase, or Cochrane Central Register of Controlled Trials (CENTRAL) between January 1, 2000, and August 12, 2022. Outcomes included exacerbation rates, prebronchodilator FEV1, and the Asthma Control Questionnaire. RESULTS: Ten randomized controlled trials (n = 9201) met eligibility. Tezepelumab (relative risk: 0.63; 95% credible interval [CI]: 0.46-0.86) was associated with significantly lower exacerbation rates than benralizumab and larger improvements in FEV1 compared to mepolizumab (mean difference [MD]: 66; 95% CI: -33 to 170) and benralizumab (MD: 62; 95% CI: -22 to 150), though the 95% CI crossed the null value of 0. Mepolizumab improved the Asthma Control Questionnaire score the most, but this improvement was not significantly different from that of tezepelumab (tezepelumab vs mepolizumab; MD: 0.14; 95% CI: -0.10 to 0.38). For efficacy by clinically important thresholds, tezepelumab, mepolizumab, and dupilumab achieved a >99% probability of reducing exacerbation rates by ≥50% compared to placebo, but benralizumab had only a 66% probability of doing so. Tezepelumab and dupilumab had a probability of 1.00 of improving prebronchodilator FEV1 by ≥100 mL above placebo. Compared to mepolizumab, dupilumab had >90% chance for improving FEV1 by ≥50 mL, but none of the differences between biologics exceeded 100 mL. CONCLUSIONS: In individuals with eosinophilic asthma, tezepelumab and dupilumab were associated with greater improvements (although below clinical thresholds) in exacerbation rates and lung function than benralizumab or mepolizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaPulmonary EosinophiliaBiological ProductsHumansBayes TheoremAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AsthmaBayesianbenralizumabcomparative effectivenessdupilumabeosinophilicmAbmepolizumabnetwork meta-analysistezepelumab

Substanzen

Anti-Asthmatic AgentsBiological ProductstezepelumabAntibodies, Monoclonal, Humanizedmepolizumabdupilumabbenralizumab

Autor:innen und Institutionen

  • Division of Allergy and Clinical Immunology, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Harvard T.H. Chan School of Public Health, Boston, Mass; Faculty of Medicine, Chulalongkorn University,…
  • Department of Anesthesiology, NewYork-Presbyterian/Weill Cornell Medical Center.
  • Harvard T.H. Chan School of Public Health, Boston, Mass; Chung Shan Medical University, Taichung, Taiwan.
  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Md; Center for Drug Safety and Effectiveness, Baltimore, Md; Department of Mental Health, Johns Hopkins Bloomberg School of Public…
  • Division of Pediatric Allergy and Immunology, University of North Carolina, Chapel Hill, NC.
  • Department of Biostatistics and Bioinformatics, Duke University, Durham, NC.

Förderung

  • NIMHD NIH HHS
  • National Institute on Minority Health and Health Disparities
  • National Institutes of Health

Zitieren

APA

Nopsopon, T., Lassiter, G., Chen, M. L., Alexander, G. C., Keet, C., Hong, H., & Akenroye, A. (2023). Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. Journal of Allergy and Clinical Immunology, 151(3), 747-755. https://doi.org/10.1016/j.jaci.2022.11.021

Vancouver

Nopsopon T, Lassiter G, Chen ML, Alexander GC, Keet C, Hong H, et al. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. Journal of Allergy and Clinical Immunology. 2023;151(3):747-755. doi:10.1016/j.jaci.2022.11.021

BibTeX
@article{Nopsopon2023,
  author = {Nopsopon, Tanawin and Lassiter, Grace and Chen, Ming-Li and Alexander, G Caleb and Keet, Corinne and Hong, Hwanhee and Akenroye, Ayobami},
  title = {Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {151},
  number = {3},
  pages = {747--755},
  doi = {10.1016/j.jaci.2022.11.021}
}
Kostenlos starten →